RecruitingLocally Advanced/Metastatic Solid Tumors
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Sponsor: InSilico Medicine Hong Kong Limited
You may qualify if…
- ✓ 1. Male or female participants with age ≥18 years at the time of signing the informed consent.
- ✓ 2. Histologically confirmed unresectable locally advanced or metastatic solid tumors with confirmed homozygous MTAP deletion, who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists.
- ✓ 3. Have measurable or evaluable lesions in Part 1 and at least one measurable target lesion in Part 2 as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- ✓ 4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤1.
- ✓ 5. Life expectancy of ≥12 weeks as judged by the investigator.
- ✓ 6. Adequate organ function as determined by medical assessment.
- ✓ 7. Capable of providing signed ICF and complying with the requirements and restrictions listed in the ICF and in this study protocol.
You may not qualify if…
- ✕ 1. Prior treated with other MAT2A inhibitors and/or PRMT inhibitors.
- ✕ 2. Participation in other therapeutic clinical studies within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment.
- ✕ 3. Anti-tumor therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-tumor therapy, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogues, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment.
- ✕ 4. Toxicities of prior therapy have not resolved to Grade ≤1 or to baseline (as evaluated by NCI CTCAE version 5.0)
- ✕ 5. History of another primary tumor that has been diagnosed or required therapy within the past 3 years.
- ✕ 6. Previous history of, or presence of Gilbert's syndrome.
- ✕ 7. Previous history of myelodysplastic syndrome.
- ✕ 8. Prior solid organ or hematopoietic stem cell transplant.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06414460 · last updated 2026-09-01